Around the Region

Cubist seeks therapies to fuel growth

NEW YORK ­— Cubist Pharmaceuticals Inc., maker of the antibiotic Cubicin, is seeking early-stage experimental therapies to buy or license to fuel growth beyond the next five years, chief executive Michael Bonney said.

Cubist expects to reach $2 billion in annual revenue, earn $700 million in profit, and have four products in late-stage clinical trials by the end of 2017, the Lexington, Mass.-based biotechnology company told investors Monday at a presentation in New York.


Cubist’s focus is acute care products used in hospitals to treat bacterial infections or aid with recovery from surgery. The company had $861.7 million in cash and equivalents as of March 31.

It has made two acquisitions since 2009, both of companies with therapies in later stages of development. The focus now is to find products to follow those, Bonney said.

“We need to be feeding that so that when we get to 2017 we have replacement stock coming” to follow the later-stage products, Bonney said.

Loading comments...
Real journalists. Real journalism. Subscribe to The Boston Globe today.
You're reading  1 of 5 free articles.
Get UNLIMITED access for only 99¢ per week Subscribe Now >
You're reading1 of 5 free articles.Keep scrolling to see more articles recomended for you Subscribe now
We hope you've enjoyed your 5 free articles.
Continue reading by subscribing to for just 99¢.
 Already a member? Log in Home
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of
Marketing image of